Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Genkyotex       FR0011790542


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news
The feature you requested does not exist. However, we suggest the following feature:

Genkyotex : Liquidity contract balance at December 31, 2018

share with twitter share with LinkedIn share with facebook
share via e-mail
01/09/2019 | 03:39pm EDT


Archamps (France), January 09, 2019 at 06:00 pm CET


Pursuant to the liquidity contract granted by Genkyotex to Kepler Cheuvreux, effective May 7, 2018, the following assets appeared on the liquidity account as of December 31, 2018:

  • 94,540 Genkyotex shares,

  • 29,622.06 in cash.

As a reminder, the following assets appeared on the liquidity account at June 30, 2018:

  • 65,870 Genkyotex shares,

  • 61,704.71 in cash.

About Genkyotex

Genkyotex is the leading biopharmaceutical company in NOX therapies, listed on the Euronext Paris and Euronext Brussels regulated markets. A leader in NOX therapies, its unique therapeutic approach is based on a selective inhibition of NOX enzymes that amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration.

Genkyotex's platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes. Genkyotex is developing a pipeline of first-in-class product candidates targeting one or multiple NOX enzymes. The lead product candidate, GKT831, a NOX1 and NOX4 inhibitor is evaluated in a phase II clinical trial in primary biliary cholangitis (PBC, a fibrotic orphan disease) and in an investigator-initiated Phase II clinical trial in Type 1 Diabetes and Kidney Disease (DKD). This product candidate may also be active in other fibrotic indications. Its second product candidate, GKT771, is a NOX1 inhibitor targeting multiple pathways in angiogenesis, pain processing, and inflammation, currently undergoing preclinical testing.

Genkyotex also has a versatile platform well-suited to the development of various immunotherapies (Vaxiclase). A partnership covering the use of Vaxiclase as an antigen per se (GTL003) has been established with Serum Institute of India Private Ltd (Serum Institute), the world's largest producer of vaccine doses, for the development by Serum Institute of cellular multivalent combination vaccines against a variety of infectious diseases. This partnership could generate approximately €150 million in future revenues for Genkyotex, before royalties on sales.

For further information, please go to www.genkyotex.com.



This press release and the information it contains does not constitute an offer or solicitation to buy, sell or hold Genkyotex shares in any country, in particular any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or other qualification under the securities laws of any such jurisdiction.

This press release may contain forward-looking statements by the company with respect to its objectives. Such statements are based upon the current beliefs, estimates and expectations of Genkyotex's management and are subject to risks and uncertainties such as the company's ability to implement its chosen strategy, customer market trends, changes in technologies and in the company's competitive environment, changes in regulations, clinical or industrial risks and all risks linked to the company's growth. These factors as well as other risks and uncertainties may prevent the company from achieving the objectives outlined in the press release and actual results may differ from those set forth in the forward-looking statements, due to various factors. Without being exhaustive, such factors include uncertainties involved in the development of Genkyotex's products, which may not succeed, or in the delivery of Genkyotex's products marketing authorizations by the relevant regulatory authorities and, in general, any factor that could affects Genkyotex's capacity to commercialize the products it develops. No guarantee is given on forward-looking statements which are subject to a number of risks, notably those described in the registration document (document de reference) registered by the French Markets Authority (the AMF) on 27 April 2018 under number R.18-037., and those linked to changes in economic conditions, the financial markets, or the markets on which Genkyotex is present. Genkyotex products are currently used for clinical trials only and are not otherwise available for distribution or sale.






LifeSci Advisors, LLC

Dušan Orešanský, Tristan Roquet

Caroline Carmagnol

Brian Ritchie

Montégon and Emmanuel Huynh

+33 6 64 18 99 59


+33 1 44 71 94 92

+33 1 44 54 36 65






Genkyotex SA published this content on 09 January 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 09 January 2019 20:38:05 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on GENKYOTEX
2019GENKYOTEX : Liquidity contract balance at December 31, 2018
2018GENKYOTEX SA : half-yearly earnings release
2018GENKYOTEX : Half-yearly report on Genkyotex's liquidity contract
2017GENKYOTEX SA : half-yearly earnings release
2017GENKYOTEX : Summary of Genkyotex's liquidity contract with ODDO Corporate Financ..
2017GENTICEL BECOMES “GENKYOTEX&RD : Genticel's General Meeting approves the s..
2017GENKYOTEX SA : annual earnings release
2017GENTICEL : Genticel becomes Genkyotex: Genticel’s General Meeting approves the s..
2017GENTICEL : Genticel announces its 2016 annual results
2017GENTICEL : Genticel updates its financial calendar for 2017
More news
Duration : Period :
Genkyotex Technical Analysis Chart | MarketScreener
Full-screen chart